54 Views | 32 Downloads
Lori A. Devlin, Email: lori.devlinphinney@louisville.edu
All authors (LAD, LWY, WKK, EMW, AC, SLM, TW, HEJ, BBP, LSW, ALS, AGM, and JMD) critically reviewed the paper outline, participated in drafting the initial paper, critically reviewed subsequent paper drafts, and approved the submitted version. All authors agree to be accountable for all aspects of the work.
The authors thank Kathryn Adams and Andrew A. Bremer from the Eunice Kennedy Shriver National Institute of Child Health and Human Development for reviewing paper drafts and providing insightful edits. The authors also wish to acknowledge the role of BioCentric staff in supporting the development of this paper, including preparing an outline and paper draft based on author presentations at the NIH HEAL Initiative℠ workshop—Toward the Use of Buprenorphine in Infants: Scientific and Practical Considerations.
These authors contributed equally: Lori A. Devlin, Leslie W. Young.
The authors declare no competing interests.
LAD reports funding from NIH HEAL for ACT NOW CE and ESC (U24 HD095254 and U2C OD023375); LWY reports funding from NIH HEAL for ACT NOW CE and ESC (U24 HD095254 and U2C OD023375), HBCD Phase I Planning Grant (1R34DA050283-01), and MOTHER DYAD (R011DA047867-01); WKK reports Thomas Jefferson University receiving research and consulting grants from Chiesi USA, Inc.; EMW reports no conflicts of interest; SLM reports funding from NIH HEAL for HBCD Phase 1 (R34 DA050268) and ACT NOW OBOE (PL1 HD101059/RL1 HD104254); TW reports the University of Cincinnati receiving research grant funding (UG1DA013732) from the National Institute on Drug Abuse, National Drug Abuse Treatment Clinical Trials Network, NIH; HEJ reports no conflicts of interest; LSW reports funding from HBCD Phase I Planning Grant (R34DA050266); ALS reports NIH HEAL research funding (R01DA015778-5); AGM is an employee of the Emmes Company which receives NIH HEAL funds through their support of the National Drug Abuse Treatment Clinical Trials Network (contract 75N95019D00013); JMD reports receiving funding from the March of Dimes to examine novel agents for preventing or treating NAS and receiving funding from NIDA, NICHD, and the Charles Hood Foundation for various studies of NAS. Funding for the role of BioCentric in supporting the development of this manuscript was provided by the Pregnancy and Perinatology Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
© The Author(s), under exclusive licence to Springer Nature America, Inc. 2021